EDN1 and hypertensive disorder: The role of ET-1 in the development of the hypertensive process is also supported by data in patients with essential HTN or resistant HTN, which show that when treated with a non-selective ET-receptor antagonist bosentan [20] or with the selective ETA receptor antagonist darusentan [21,22,23], BP is significantly reduced.